ATHENS, Ga., March 27 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its CELL-EZ(TM) brand hMC(TM) human mesenchymal progenitor cells commercially available to the research community in mid 2009. Derived from pluripotent human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer culture.
The introduction of our CELL-EZ hMC(TM) cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO and Co-Founder commented, "CELL-EZ hMC(TM) will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis."
The CELL-EZ hMC(TM) cell lines were further developed by ArunA through a technology license agreement with the
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases such as Parkinson's, Alzheimer's, Huntington's and cancer.
For more information, visit: www.ArunAbiomedical.com.
This press release contains forward-looking statements regarding the company's potential impact on scientific research. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.
|SOURCE ArunA Biomedical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved